www.hivandhepatitis.com

CROI 2015: PrEP Provides 86% Protection in 2 Studies [VIDEO]

Among the most eagerly anticipated and well received news at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) last week in Seattle were a pair of reports showing that Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis, or PrEP, taken either daily or before and after sex, reduced the likelihood of HIV infection by 86%. In both studies, no one who took PrEP consistently became infected.

[Sheena McCormack and Jean-Michel Molina, CROI, February 24, 2015]

Sheena McCormack from University College London reported results from the UK English PROUD study, in which gay and bisexual men were randomly assigned to start once-daily Truvada immediately or after 1 year. This study demonstrated the highest effectiveness yet seen for this PrEP method. PROUD saw 3 new HIV infections in the immediate PrEP group compared to 19 in the deferred group; treating 13 people with daily Truvada for a year would be expected to prevent 1 infection.

Jean-Michel Molina from University of Paris Diderotpresented findings from the French Ipergay study. This trial looked at event-driven or "on-demand" PrEP taken before and after sex, rather than daily. In Ipergay there were 2 new HIV infections in the intermittent PrEP group compared with 14 in the placebo group; treating 18 people for a year would be expected to prevent 1 infection.

McCormack and Molina summarized their findings at a CROI press conference following their presentations.

"These results are extremely exciting and show PrEP is highly effective at preventing HIV infection in the real world," said McCormack.

SEE ALSO:

CROI 2015: PrEP Stops 86% of HIV Infections in PROUD Study

CROI 2015: On-Demand PrEP Prevents 86% of HIV Infections in Ipergay

3/6/15

References

S McCormack and D Dunn for PROUD Study Group. Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 22LB.

JM Molina, CCapitant, B Spire, et al for ANRS Ipergay Study Group. Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 23LB.